Unlocking Bioanalytical Excellence: Vito Saccente and John Ryan Unveil Resolian's Dynamic Capabilities

December 14, 2023 / by Resolian

SelectScience_VS&JRDiscover the extensive experience of our team in the realm of bioanalytical assay development, validation, and sample analysis. Join Vito Saccente and John Ryan in this insightful video as they shed light on our comprehensive support, spanning the entire spectrum from early drug evaluation to clinical trials.

Filmed at AAPS 2023 PharmSci 360, this video showcases how our flexibility and agility align perfectly with the specific demands of our clients.

🎥. To gain valuable insights into Resolian's commitment and global expertise, watch the video


Exploring Resolian's Global Vision with CEO Patrick Bennett

December 14, 2023 / by Resolian

SelectScience_PBJoin CEO Patrick Bennett in an exclusive video where he delves into the mission, vision, and values that drive us. Filmed at AAPS 2023 PharmSci 360, this insightful discussion highlights our commitment to excellence in the analytical and bioanalytical space.

Our journey has been marked by its evolution from Alliance Pharma Inc. and Drug Development Solutions Ltd. Patrick Bennett shares strategic insights into our recent expansion into the Chinese market. In this interview, Pat elaborates on the distinctive expertise embedded within each of Resolian's four global laboratories, emphasizing the synergy and harmonization meticulously maintained across the organization.

🎥 Learn more about Resolian's global endeavours by watching the video


Learn more about our global team at Resolian

December 6, 2023 / by Resolian

Dive into an insightful interview with Min Meng, President of Resolian Bioanalytics Chongqing and esteemed member of the editorial board of the Journal of Bioanalysis. 

In the interview, Min shares her journey from small regional labs to a global CRO, highlighting her passion for research and the impact of sharing knowledge in the scientific community.

“I like to write papers and posters…This is not driven for my personal fame or gain.

I typically must write these during my personal time. It is because of my passion for research, the scientific mind and curiosity and the belief of having a greater impact by sharing our knowledge and findings in the scientific community”.


Resolian Acquires China-Based Bioanalytical CRO Denali Medpharma

November 1st, 2023 9:00 AM / by Resolian


Resolian, a global bioanalytical contract research organization (CRO) specializing in drug metabolism and pharmacokinetics for small and large molecules, has acquired Denali MEd pharma, a leading China-based bioanalytical CRO. Resolian now has bioanalysis laboratory operations in the U.S., U.K., Australia, and China. The company can initiate a project on four continents and easily transfer validated methods across labs, allowing therapeutic trials to extend to virtually any destination without changing bioanalytical CROs. 





Alliance Pharma and Drug Development Solutions Are Now Resolian

May 18th, 2023 8:00 AM / by Alliance Pharma


Alliance Pharma, a global leader providing bioanalytical, DMPK, and CMC testing services in the pharmaceutical and biopharmaceutical industry, and Drug Development Solutions, Ltd. (acquired in 2022), today announced they will be operating under the new name Resolian — fully integrating the companies into one organization. This brings together the companies’ established bioanalytical laboratories and experts in the U.S., U.K., and most recently in Australia, as Resolian continues to expand and support the growing need for small and large molecule bioanalytical and analytical services globally.


Alliance Pharma Opens State-of-the-Art Bioanalytical Laboratory in Brisbane

December 7, 2022 8:00 AM / by Alliance Pharma

AustraliaMALVERN, Pa.; December 7, 2022 (Business Wire) – Alliance Pharma (Alliance), a global leader providing bioanalytical, DMPK, and CMC testing services in the pharmaceutical and biopharmaceutical industry, has opened its new 20,000-square-foot (1,858-square-meter) bioanalytical laboratory, Alliance Pharma Pty, Ltd., in Brisbane, Australia.

The new Australia facility, which the company announced plans for earlier this summer, includes an expansive lab to provide much-needed small and large molecule bioanalytical services for a region with limited choices for bioanalytical support.


U.S. Alliance Pharma Expands Early Phase Bioanalytical Services Into Australia

MALVERN, Pa. and BRISBANE, Australia; Aug. 11, 2022 – Alliance Pharma (Alliance), a global leader in bioanalytical and CMC testing services in the pharmaceutical and biopharmaceutical industry, today announced they will be opening a bioanalytical laboratory, Alliance Pharma Pty, Ltd., in Brisbane, Australia. The 20,000-square-foot purpose-built facility supporting preclinical and clinical testing will be fully operational in November 2022.

Alliance Pharma Pty, Ltd. will contain an expansive state-of-the-art lab, providing much-needed small and large molecule bioanalytical services for a region that currently has limited choices for bioanalytical support. Alliance will . . .


U.S. Alliance Pharma Acquires U.K.-based LGC’s Drug Development Solutions (DDS) Business

Expands bioanalytical services to include many emerging areas worldwide

Merge_png_small4MALVERN, Pa.; July 13, 2022 (Business Wire) – Alliance Pharma (Alliance), a U.S. leader in small and large molecule bioanalytical services in the pharmaceutical and biopharmaceutical industry, today closed on the purchase of Drug Development Solutions (DDS), a U.K.-based bioanalytical and material science testing contract research organization (CRO), from LGC. Ampersand Capital Partners, a global healthcare private equity firm, and KKR & Co. Inc. (KKR) (NYSE:KKR), a leading global investment firm, are equal shareholders in the combined company.



AlliancePharma Announces Launch of Professional Services Quoting Application, PSQuote from CLD Partners

 Apr 29, 2022 3:57:19 PM / by Alliance Pharma

MALVERN, Pa., April 29, 2022 /PRNewswire/ -- logo@2x_CLDThis week, AlliancePharma (Malvern, PA) announced their go-live of PSQuote together with CLD Partners (Front Royal, VA). PSQuote is a newly developed professional services quoting application built on the Salesforce platform (PSQuote is a wholly-owned division of CLD Partners). AlliancePharma will use the tool to enhance and elevate their sales cycle, delivering a better customer sales experience--from quote to service delivery. CLD Partners has engaged with AlliancePharma since June 2021, for FinancialForce implementation services, and this new deployment is the next step in a growing business relationship. . . 


Alliance Pharma Appoints Patrick Bennett as Chief Executive Officer

Apr 12, 2022 4:51:57 PM / by Alliance Pharma 

Alliance_Pat__Announce1pngMalvern, PA, March 25, 2022 - Alliance Pharma, a leader in small and large molecule bioanalytical services in the pharmaceutical and biopharmaceutical industry, announces that Patrick Bennett has been named Chief Executive Officer. Bennett has more than 30 years of experience in the industry, including 25 years in leadership roles at various bioanalytical contract research organizations, most recently as Vice President, Strategy and . . . 


Ampersand Invests in Alliance Pharma, Leading Bioanalytical CRO

Nov 19, 2021 10:23:36 AM / by Alliance Pharma 

logo_ampersandWELLESLEY, MA, November 18, 2021 /PRNewswire/ -- Ampersand Capital Partners, a private equity firm specializing in growth equity investments in the healthcare sector, has announced an investment in Alliance Pharma (“Alliance”), a global leader in large and small molecule bioanalytical services. Headquartered in Malvern, PA., Alliance provides a full suite of discovery bioanalytical, DMPK, regulated bioanalysis, biomarker, LC-MS/MS, immunoassay, and cell and gene therapy assays. These capabilities support preclinical-through-Phase 4 studies run by a global customer base comprised of leading pharma and biotech companies.